Normal tissue BRCA1 methylation associated with risk for high-grade ovarian cancer
1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC).
2. BRCA1 methylation was detected in women of all ages, including newborns, suggesting that BRCA1 methylation happens at an embryonic stage.
Study Rundown: Females with BRCA1 mutations in their germline have a high risk of HGSOC. However, BRCA1 methylation in normal tissues has also been detected in some families who are at high risk of breast cancer but do not have BRCA1 mutations in their germline. The authors of this case-control study aimed to evaluate possible links between BRCA1 methylation in normal tissue and risk for ovarian cancer. Researchers examined the WBCs of 934 patients and 1 698 healthy controls using methylation-specific quantitative polymerase chain reaction (qPCR). The authors found that BRCA1 promoter methylation in normal tissue had a positive association with risk for HGSOC. Results were confirmed through a validation study. The authors detected BRCA1 methylation in women of all ages, including newborns. This suggests that BRCA1 methylation likely happens at an embryonic stage and may affect future risk of HGSOC.
A strength of this study is that its conduction was consistent with the STREGA (Strengthening the Reporting of Genetic Association Studies) and GRIPS (Strengthening the Reporting of Genetic Risk Prediction Studies) statements. A limitation of the study is that due to the difficult logistics of a prospective study design, a retrospective one was used: blood samples were collected from recruited ovarian cancer patients at the time of their diagnosis.
In-Depth [case-control study]: Using methylation-specific qPCR, the authors compared the BRCA1 promoter methylation status in the WBCs of 934 patients with those of 1 698 healthy controls in a preliminary study. The authors conducted a similar analysis of 607 patients and 1 984 healthy controls in a validation study. The patients were selected from two hospitals in Norway, and all blood samples were taken before the patients underwent chemotherapy. Researchers found that BRCA1 methylation was present more often in ovarian cancer patients (6.4%) than healthy controls (4.2%). Elevated methylation was limited to HGSOC patients (9.6%) compared to patients with nonserous (5.1%) and low-grade serous (4.0%) ovarian cancer. The validation study produced similar results for HGSOC patients (9.1%), healthy controls (4.3%), nonserous ovarian cancer (4.1%), and low-grade serous ovarian cancer (2.7%). WBC subfractions, tumor burden, and sample storage time did not affect the results. WBC BRCA1 methylation was found most frequently in newborns (7.0% compared to 4.1% in young women).
©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|